For example, the use of anti-HER-2/neu antibodies (e.g., trastuzumab) in combination with DCs can significantly enhance the HER-2-specific CTL response, thereby improving tumor cell clearance (11) (Table 1, Figure 2). Here, ERBB2 is linked to neoplasm.